Credits Earned (2024) Crédits obtenus

Redeem Prepaid Membership

Tools for Practice Outils pour la pratique


#99 Will the Flu Shot Help my Grandma and Grandpa?


CLINICAL QUESTION
QUESTION CLINIQUE
Does the seasonal trivalent influenza vaccine (flu shot) prevent influenza or its complications in patients age ≥65 years old?


BOTTOM LINE
RÉSULTAT FINAL
One high quality randomized controlled trial demonstrated that vaccinating 40 community dwelling seniors with the trivalent influenza vaccine (flu shot) will prevent one case of influenza. Cohort studies demonstrating mortality benefits are biased by healthy user effect.  



CFPCLearn Logo

Reading Tools for Practice Article can earn you MainPro+ Credits

La lecture d'articles d'outils de pratique peut vous permettre de gagner des crédits MainPro+

Join Now S’inscrire maintenant

Already a CFPCLearn Member? Log in

Déjà abonné à CMFCApprendre? Ouvrir une session



EVIDENCE
DONNÉES PROBANTES
Meta-analysis evaluating cohort and randomized controlled studies of influenza vaccine in patients 65 years concluded they are unable to determine effectiveness of the vaccine.1  Randomized Controlled Trials (RCTs) of community-dwelling patients:  
  • Netherlands: Double blinded RCT of flu shot versus placebo in 1,838 patients, mean age 67 years, 87% without previous vaccination.2,3  
    • Influenza (influenza-like illness plus serology)Vaccine 1.7%, placebo 4.2%, Number Needed to Treat (NNT)=40. 
    • Mortality rates not reported. 
    • Adverse events: Local reactions more common, systemic effects similar.3 
  • United Kingdom: Smaller, single-blindedless generalizable (729 patients with co-morbidities excludedplacebo-controlled RCT of flu shot after all received pneumococcal vaccine.4  
    • No difference in influenza, pneumonia, hospitalization for respiratory illness or mortality. 
  • RCT of 614 nursing home patientsLower quality, multi-armedplacebo-controlled RCT of flu shot +/- live intranasal vaccine.5  
    • Only the combination of flu shot plus live intranasal vaccine significantly decreased influenza rates (4.5% versus 12.8% placebo, NNT=13). 
    • Study appears underpowered to show benefits of other interventions. 
    • Mortality rates not reported. 
Context:  
  • Cohort studies demonstrated large reductions in hospitalizations and mortality, but are confounded by healthy user effect1 as:  
    • Benefits seen outside of influenza season. 
    • Overall mortality reduction is greater than reduction in influenza, hospitalizations, and deaths due to respiratory illnesses.  
  • Based on this observational data, Canadian guidelines recommend vaccinating elderly to decrease influenza related morbidity and mortality.6 
  • For Canadians ≥65 years, the annual influenza death rate is ~100/100,000.7,8  
    • Cardiovascular disease and cancer deaths are at least 25 times more common.8 
updated jan 29 2018 by ricky


Latest Tools for Practice
Derniers outils pour la pratique

#367 Oral Calcitonin Gene-related Peptide Antagonists: A painfully long name for the acute treatment of migraines

What are the risks and benefits of ubrogepant for the acute treatment of episodic migraines?
Read Lire 0.25 credits available Crédits disponibles

#366 Looking for Closure: Managing simple excisions or wounds efficiently

What are some options for efficiency in wound closure?
Read Lire 0.25 credits available Crédits disponibles

#365 Shrooms for Glooms: Evidence for psilocybin for depression

What are the benefits and harms of psilocybin for treatment-resistant/recurrent depression?
Read Lire 0.25 credits available Crédits disponibles

This content is certified for MainPro+ Credits, log in to access

Ce contenu est certifié pour les crédits MainPro+, Ouvrir une session


Author(s)
Auteur(s)
  • Christina Korownyk MD CCFP
  • Darren Lau PhD
  • Michael R Kolber MD CCFP MSc

1. Jefferson T, Di Pietrantonj C, Al-Ansary LA, et al. Cochrane Database Syst Rev. 2010; 2:CD004876.

2. Govaert ME, Thijs CTM, Masurel N, et al. JAMA. 1994; 272:1661-5.

3. Govaert ME, Dinant GJ, Aretz K, et al. BMJ. 1993; 307:988-90.

4. Allsup S, Haycox A, Regan M, et al. Vaccine. 2004; 23:639-45.

5. Rudenkoa LG, Ardenb NH, Grigorievaa E, et al. Vaccine. 2000; 19:308-18.

6. National Advisory Committee on Immunization. Can Commun Dis Rep Wkly. 2012; 38 (ACS-2):1-36.

7. Schanzer DL, Tam TWS, Langley JM, et al. Epidemiol Infect. 2007; 135: 1109-16.

8. Public Health Agency of Canada. Available from: http://publichealth.gc.ca/CPHOreport. Last Accessed: September 4, 2013.

Authors do not have any conflicts of interest to declare.

Les auteurs n’ont aucun conflit d’intérêts à déclarer.

Most recent review: 29/01/2018

By: Ricky D. Turgeon BSc(Pharm) ACPR PharmD

Comments:

Evidence Updated: None; Bottom Line: No change.

Learning at a glance
Yearly credits
Acquired ()
Your content by topic
Cardiology Dermatology Emergency
My Bookmarks